Drug Profile
Toralizumab
Alternative Names: Anti-5c8 - IDEC; Anti-CD154 - IDEC; Anti-CD40L - IDEC; Anti-gp39 - IDEC; Anti-gp39 monoclonal antibody - IDEC; Anti-T-BAM - IDEC; Anti-TRAP - IDEC; E 6040; IDEC 131Latest Information Update: 05 Jul 2007
Price :
$50
*
At a glance
- Originator IDEC Pharmaceuticals
- Developer Eisai Co Ltd; IDEC Pharmaceuticals; Seikagaku Corporation
- Class Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Crohn's disease; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 04 Aug 2004 Phase-I clinical trials in Autoimmune disorders in Japan (unspecified route)
- 30 Apr 2003 IDEC Pharmaceutical is working with the FDA to remove the clinical hold status on IDEC 131
- 09 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) was added to the adverse events section and the Skin therapeutic trials section